Matthew Karolak
Graduate student
Last active: 11/21/2014

Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.

Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH
Cancer Chemother Pharmacol. 2013 71 (6): 1567-76

PMID: 23572175 · PMCID: PMC3669633 · DOI:10.1007/s00280-013-2156-3

PURPOSE - Bortezomib, a first-generation proteasome inhibitor, induces an endoplasmic reticulum (ER) stress response, which ultimately leads to dysregulation of intracellular Ca(2+) and apoptotic cell death. This study investigated the role of the Ca(2+)-dependent enzyme, calpain, in bortezomib cytotoxicity. A novel therapeutic combination was evaluated in which HIV protease inhibitors were used to block calpain activity and enhance bortezomib cytotoxicity in myeloma cells in vitro and in vivo.

METHODS - Bortezomib-mediated cell death was examined using assays for apoptosis (Annexin V staining), total cell death (trypan blue exclusion), and growth inhibition (MTT). The effects of calpain on bortezomib-induced cytotoxicity were investigated using siRNA knockdown or pharmaceutical inhibitors. Enzyme activity assays and immunofluorescence analysis were used to identify mechanistic effects.

RESULTS - Inhibition of the Ca(2+)-dependent cysteine protease calpain, either by pharmacologic or genetic means, enhances or accelerates bortezomib-induced myeloma cell death. The increase in cell death is not associated with an increase in caspase activity, nor is there evidence of greater inhibition of proteasome activity, suggesting an alternate, calpain-regulated mechanism of bortezomib-induced cell death. Bortezomib initiates an autophagic response in myeloma cells associated with cell survival. Inhibition of calpain subverts the cytoprotective function of autophagy leading to increased bortezomib-mediated cell death. Combination therapy with bortezomib and the calpain-blocking HIV protease inhibitor, nelfinavir, reversed bortezomib resistance and induced near-complete tumor regressions in an SCID mouse xenograft model of myeloma.

MeSH Terms (19)

Animals Antineoplastic Agents Apoptosis Autophagy Boronic Acids Bortezomib Calpain Cell Line, Tumor Cell Survival Drug Synergism HIV Protease Inhibitors Humans Mice Mice, SCID Multiple Myeloma Nelfinavir Pyrazines RNA, Small Interfering Xenograft Model Antitumor Assays

Connections (1)

This publication is referenced by other Labnodes entities:

Links